晚期糖基化终末产物与骨性关节炎相关性的研究进展Current research on the correlation between advanced glycation end products and osteoarthritis
黄文舟;殷嫦嫦;敖鹏;程细高;
摘要(Abstract):
晚期糖基化终末产物(advanced glycation end products,AGEs)是衰老致骨性关节炎的重要因素,主要通过受体(receptors for advanced glycation end products,RAGE)途径,引起软骨基质降解与软骨细胞凋亡、促进软骨及滑膜组织的炎性反应等方式在OA发病中发挥重要作用。AGEs是OA领域的研究新热点,但其分子机制还未完全阐明,对AGEs的研究将有助于明确OA的发病机制,同时为OA的治疗策略提供了新的观念。
关键词(KeyWords): 骨性关节炎;晚期糖基化终末产物;软骨;细胞凋亡
基金项目(Foundation):
作者(Author): 黄文舟;殷嫦嫦;敖鹏;程细高;
Email:
DOI:
参考文献(References):
- [1]Shane Anderson A,Loeser RF.Why is osteoarthritis an age-related disease[J].Best Pract Res Clin Rheumatol,2010,24(1):15-26.
- [2]Prasad C,Imrhan V,Marotta F,et al.Lifestyle and advanced glycation end products(AGEs)burden:its relevance to healthy aging[J].Aging Dis,2014,5(3):212-217.
- [3]Sanguineti R,Puddu A.Advanced glycation end products play ad-verse proinflammatory activities in osteoporosis[J].Mediat Inflammation,2014,2014(9):975872.
- [4]Verzijl N,De Groot J,Oldehinkel E,et al.Age-related accumulation of Maillard reaction products in human articular cartilage collagen[J].Biochem J,2000,350,2:381-387.
- [5]Handl M,FilováE,Kubala M,et al.Fluorescent advanced glycation end products in the detection of factual stages of cartilage degeneration[J].Physiol Res,2007,56(2):235-242.
- [6]Kim JH,Lee G,Won Y,et al.Matrix cross-linking-mediated mechanotransduction promotes posttraumatic osteoarthritis[J].Proc Natl Acad Sci USA,2015,112(30):9424-9429.
- [7]Braun M,HulejováH,GatterováJ,et al.Pentosidine,an advanced glycation end-product,may reflect clinical and morphological features of hand osteoarthritis[J].Open Rheumatol J,2012,6(1):64-69.
- [8]Senolt L,Braun M,OlejárováM,et al.Increased pentosidine,an advanced glycation end product,in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein[J].Ann Rheum Dis,2005,64(6):886-890.
- [9]Bonet ML,Granados N,Palou A.Molecular players at the intersection of obesity and osteoarthritis[J].Curr Drug Targets,2011,12(14):2103-2128.
- [10]Avery NC,Bailey AJ.The effects of the Maillard reaction on the physical properties and cell interactions of collagen[J].Pathol Biol,2006,54(7):387-395.
- [11]马春辉,阎作勤,郭常安,等.Ⅱ型胶原与Bcl-2在骨关节炎软骨细胞中的表达[J].中国矫形外科杂志,2012,20(19):1786-1789.
- [12]Nah SS,Choi IY,Yoo B,et al.Advanced glycation end products increases matrix metalloproteinase-1,-3,and-13,and TNF-alpha in human osteoarthritic chondrocytes[J].FEBS Lett,2007,581(9):1928-1932.
- [13]Huang CY,Lai KY,Hung LF,et al.Advanced glycation end products cause collagen II reduction by activating Janus kinase/signal transducer and activator of transcription 3 pathway in porcine chondrocytes[J].Rheumatology,2011,50(8):1379-1389.
- [14]Andreas K,H?upl T,Lübke C,et al.Antirheumatic drug response signatures in human chondrocytes:potential molecular targets to stimulate cartilage regeneration[J].Arthritis Res Ther,2009,11(1):R15.
- [15]Ma C,Zhang Y,Li YQ,et al.The role of PPARgamma in advanced glycation end products-induced inflammatory response in human chondrocytes[J].Plo S One,2015,10(5):e0125776.
- [16]Chen C,Ma C,Zhang Y,et al.Pioglitazone inhibits advanced glycation end product-induced TNF-alpha and MMP-13 expression via the antagonism of NF-kappa B activation in chondrocytes[J].Pharmacology,2014,94(5-6):265-272.
- [17]刘弼,肖德明,雷鸣,等.白藜芦醇对硝普钠诱导的软骨细胞凋亡bax及bcl-2表达的影响[J].中国矫形外科杂志,2012,20(13):1235-1238.
- [18]丁舒晨,秦子力,尹战海,等.活性氧在骨性关节炎发病中的作用机制[J].中国矫形外科杂志,2015,23(17):1587-1590.
- [19]Wong A,Dukic-Stefanovic S,Gasic-Milenkovic J,et al.Anti-inflammatory antioxidants attenuate the expression of inducible nitric oxide synthase mediated by advanced glycation endproducts in murine microglia[J].Eur J Neurosci,2001,14(12):1961-1967.
- [20]Wen L,Qu TB,Zhai K,et al.Gallic acid can play a chondroprotective role against AGE-induced osteoarthritis progression[J].J Orthop Sci,2015,20(4):734-741.
- [21]Yamabe S,Hirose J,Uehara Y,et al.Intracellular accumulation of advanced glycation end products induces apoptosis via endoplasmic reticulum stress in chondrocytes[J].FEBS J,2013,280(7):1617-1629.
- [22]Yang Q,Guo S,Wang S,et al.Advanced glycation end products-induced chondrocyte apoptosis through mitochondrial dysfunction in cultured rabbit chondrocyte[J].Fundamental Clin Pharmacol,2015,29(1):54-61.
- [23]Huang CY,Hung LF,Liang CC,et al.COX-2 and i NOS are critical in advanced glycation end product-activated chondrocytes in vitro[J].Eur J Clin Invest,2009,39(5):417-428.
- [24]Nah SS,Choi IY,Lee CK,et al.Effects of advanced glycation end products on the expression of COX-2,PGE2 and NO in human osteoarthritic chondrocytes[J].Rheumatology,2008,47(4):425-431.
- [25]Rasheed Z,Haqqi TM.Endoplasmic reticulum stress induces the expression of COX-2 through activation of e IF2α,p38-MAPK and NF-κB in advanced glycation end products stimulated human chondrocytes[J].Biochim Biophys Acta,2012,1823(12):2179-2189.
- [26]Liu FC,Hung LF,Wu WL,et al.Chondroprotective effects and mechanisms of resveratrol in advanced glycation end productsstimulated chondrocytes[J].Arthritis Res Ther,2010,12(5):R167.
- [27]Fuchs S,Skwara A,Bloch M,et al.Differential induction and regulation of matrix metalloproteinases in osteoarthritic tissue and fluid synovial fibroblasts[J].Osteoarthritis Cartilage,2004,12(5):409-418.
- [28]Drinda S,Franke S,Canet CC,et al.Identification of the advanced glycation end products N(epsilon)-carboxymethyllysine in the synovial tissue of patients with rheumatoid arthritis[J].Ann Rheumatic Dis,2002,61(6):488-492.
- [29]Franke S,Sommer M,Ruster C,et al.Advanced glycation end products induce cell cycle arrest and proinflammatory changes in osteoarthritic fibroblast-like synovial cells[J].Arthritis Res Ther,2009,11(5):R136.
- [30]Li Z,Zhou Y,Chen W,et al.Advanced glycation end products biphasically modulate bone resorption in osteoclast-like cells[J].Am J Physiol Endocrinol Metabol,2016,310(5):355-366.
- [31]Chen Y J,Chan DC,Chiang CK,et al.Advanced glycation endproducts induced VEGF production and inflammatory responses in human synoviocytes via RAGE-NF-kappa B pathway activation[J].J Orthop Res,2015,34(5):791-800.